We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $214M
1-Year Est. Return 185.33%
This Fund
S&P 500
This Quarter Est. Return
+12.02%
1 Year Est. Return
+185.33%
3 Year Est. Return
+327.48%
5 Year Est. Return
+458.62%
10 Year Est. Return
+1,549.55%
AUM
$142M
AUM Growth
+$4.53M
Cap. Flow
+$996K
Cap. Flow %
0.7%
Top 10 Hldgs %
70.5%
Holding
62
New
2
Increased
5
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
BDSX icon
Biodesix
BDSX
+$1.08M
2
PRTA icon
Prothena Corp
PRTA
+$518K
3
VTYX
Ventyx Biosciences
VTYX
+$266K
4
SRPT icon
Sarepta Therapeutics
SRPT
+$252K
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$131K

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$602K
2
CGEM icon
Cullinan Oncology
CGEM
+$269K
3
FHTX icon
Foghorn Therapeutics
FHTX
+$257K
4
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$225K
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$40K

Sector Composition

Rank Sector Weight
1 Healthcare 94.1%
2 Energy 5.82%
3 Consumer Staples 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCGO icon
26
DocGo
DCGO
$39.8M
$1.09M 0.77%
110,000
– –
CCXI
27
DELISTED
ChemoCentryx, Inc.
CCXI
$1.03M 0.73%
20,000
– –
ETRN
28
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
$995K 0.7%
133,050
– –
TSVT
29
DELISTED
2seventy bio
TSVT
$871K 0.61%
59,833
– –
PXD
30
DELISTED
Pioneer Natural Resource Co.
PXD
$823K 0.58%
3,800
– –
APLS
31
DELISTED
Apellis Pharmaceuticals
APLS
$820K 0.58%
12,000
– –
NARI
32
DELISTED
Inari Medical, Inc. Common Stock
NARI
$726K 0.51%
10,000
– –
IMGN
33
DELISTED
Immunogen Inc
IMGN
$717K 0.5%
150,000
– –
ARVN icon
34
Arvinas
ARVN
$614M
$667K 0.47%
15,000
– –
BLUE
35
DELISTED
bluebird bio
BLUE
$620K 0.44%
4,900
– –
KALV
36
DELISTED
KalVista Pharmaceuticals
KALV
$580K 0.41%
40,000
– –
IRTC icon
37
iRhythm Holdings
IRTC
$4.06B
$501K 0.35%
4,000
– –
GTHX
38
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$500K 0.35%
40,000
– –
SILK
39
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$450K 0.32%
10,000
– –
ISEE
40
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$449K 0.32%
25,000
+10,000
+67% +$131K
NKTR icon
41
Nektar Therapeutics
NKTR
$2.53B
$410K 0.29%
8,533
– –
SLNO
42
DELISTED
Soleno Therapeutics
SLNO
$409K 0.29%
245,127
– –
FOLD
43
DELISTED
Amicus Therapeutics
FOLD
$397K 0.28%
38,000
– –
KNSA icon
44
Kiniksa Pharmaceuticals
KNSA
$6.08B
$385K 0.27%
30,000
– –
XENE icon
45
Xenon Pharmaceuticals
XENE
$5.79B
$361K 0.25%
10,000
– –
CGEM icon
46
Cullinan Oncology
CGEM
$1.42B
$322K 0.23%
25,114
-20,000
-44% -$269K
PTGX icon
47
Protagonist Therapeutics
PTGX
$9.43B
$320K 0.23%
38,000
– –
XNCR icon
48
Xencor
XNCR
$1.98B
$320K 0.23%
12,300
– –
SRPT icon
49
Sarepta Therapeutics
SRPT
$2.38B
$276K 0.19%
+2,500
New +$252K
BCRX icon
50
BioCryst Pharmaceuticals
BCRX
$2.55B
$252K 0.18%
20,000
– –
1
2
3

Similar funds

EFIC
Eliot Finkel Investment Counsel Beverly Hills, California $214M AUM 62.72% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
TCM
Tassel Capital Management Matthews, North Carolina $214M AUM 16.99% 1-Year Est. Return
EFS
Econ Financial Services Harrisburg, Pennsylvania $214M AUM 10.53% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return
KWM
Kingsman Wealth Management Pensacola, Florida $214M AUM 46.9% 1-Year Est. Return
FA
Fortis Advisors Wayne, Pennsylvania $214M AUM 41.3% 1-Year Est. Return
MSWM
Mader & Shannon Wealth Management Kansas City, Missouri $214M AUM 23.75% 1-Year Est. Return

Birchview Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Birchview Capital held 62 positions worth $142M, up 3.3% from $137M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Birchview Capital's Q3 2022 filing shows 2 new, 5 increased, 4 reduced and 2 closed positions. Its largest new stake was Sarepta Therapeutics: 2,500 shares worth $276K. The largest sale was Turning Point Therapeutics, Inc. Common Stock, an estimated $602K.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 94% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q3 2022 buy was Sarepta Therapeutics: 2,500 shares worth $276K.
  • Birchview Capital added most to Biodesix in Q3 2022, an estimated $1.08M increase.
  • Birchview Capital's biggest Q3 2022 reduction was Cullinan Oncology, cutting an estimated $269K.
  • Birchview Capital fully exited Turning Point Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $602K.
  • Birchview Capital's ten largest holdings make up 71% of its $142M portfolio in Q3 2022.
  • Birchview Capital opened 2 new positions and closed 2 in Q3 2022.
  • Birchview Capital's portfolio value rose 3.3% quarter-over-quarter to $142M.

Based on Birchview Capital's 13F filing for Q3 2022, filed 7 Nov 2022.